Gastrointestinal effects of selective and non-selective non-steroidal anti-inflammatory drugs

被引:46
作者
Akarca, US [1 ]
机构
[1] Ege Univ, Sch Med, Div Gastroenterol, Izmir, Turkey
关键词
nonsteroidal anti-inflammatory drug; cyclooxygenase; prostaglandin; gastrointestinal complications;
D O I
10.2174/1381612053764904
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most commonly prescribed group of drugs. Patients receiving NSAIDs often experience abdominal discomfort, and some of them develop serious gastrointestinal complications, such as ulceration, bleeding, perforation, or obstruction. Gastrointestinal side effects of NSAIDs are mostly attributed to cyclooxygenase (COX) inhibition resulting in reduction of prostaglandin in gastric mucosa. Topical irritant effects are also contributed to their systemic effect of prostaglandin inhibition. Anti-inflammatory effects of NSAIDs are mediated by COX-2 inhibition, while COX-1 inhibition is responsible for gastric prostaglandin inhibition. Management of gastrointestinal complications of NSAIDs is costly. In order to prevent or treat the gastrointestinal complications of NSAIDs, anti-ulcer drugs can be used concomitantly. Other alternative is the application or substitution of COX-2 selective inhibitors. which spare gastric mucosal prostaglandin synthesis and do not damage the gastric mucosa. Application of COX-2 selective inhibitors as a first line treatment for arthritic disorders may not be cost-effective, if patients do not have any risk factors including advanced age, history of complicating peptic ulcer, concomitant anticoagulant and corticosteroid medication. Patients with risk factors or those developing gastrointestinal complications during the course of NSAID treatment can be treated with COX-2 selective inhibitors if necessary.
引用
收藏
页码:1779 / 1793
页数:15
相关论文
共 90 条
[1]   Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs:: A case-control study [J].
Aalykke, C ;
Lauritsen, JM ;
Hallas, J ;
Reinholdt, S ;
Krogfelt, K ;
Lauritsen, K .
GASTROENTEROLOGY, 1999, 116 (06) :1305-1309
[2]   GASTRODUODENAL MUCOSAL PROTECTION [J].
ALLEN, A ;
FLEMSTROM, G ;
GARNER, A ;
KIVILAAKSO, E .
PHYSIOLOGICAL REVIEWS, 1993, 73 (04) :823-857
[3]   NONSTEROIDAL ANTIINFLAMMATORY DRUGS AND LIFE THREATENING COMPLICATIONS OF PEPTIC-ULCERATION [J].
ARMSTRONG, CP ;
BLOWER, AL .
GUT, 1987, 28 (05) :527-532
[4]   Oral valdecoxib and injected parecoxib for acute postoperative pain: A quantitative systematic review [J].
Jodie Barden ;
Jayne E Edwards ;
Henry J McQuay ;
R Andrew Moore .
BMC Anesthesiology, 3 (1)
[5]   Double-blind, placebo-controlled study on effect of diclofenac sodium and indomethacin on postprandial gastric motility in man [J].
Bassotti, G ;
Bucaneve, G ;
Furno, P ;
Morelli, A ;
Del Favero, A .
DIGESTIVE DISEASES AND SCIENCES, 1998, 43 (06) :1172-1176
[6]   Helicobacter pylori infection and the use of NSAIDs [J].
Bazzoli, F ;
De Luca, L ;
Graham, DY .
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2001, 15 (05) :775-785
[7]  
BIJLSMA JWJ, 1988, ALIMENT PHARM THERAP, V2, P85
[8]   Emergency admissions for upper gastrointestinal disease and their relation to NSAID use [J].
Blower, AL ;
Brooks, A ;
Fenn, GC ;
Hill, A ;
Pearce, MY ;
Morant, S ;
Bardhan, KD .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1997, 11 (02) :283-291
[9]   Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J].
Bombardier, C ;
Laine, L ;
Reicin, A ;
Shapiro, D ;
Burgos-Vargas, R ;
Davis, B ;
Day, R ;
Ferraz, MB ;
Hawkey, CJ ;
Hochberg, MC ;
Kvien, TK ;
Schnitzer, TJ ;
Weaver, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) :1520-1528
[10]  
Campbell DR, 2002, AM J GASTROENTEROL, V97, P2208, DOI 10.1111/j.1572-0241.2002.05774.x